Brief: Regenxbio Announces New Positive Data From Affinity Duchenne Trial Of RGX-202

Regenxbio

01/08/2024 12:34

Aug 1 (Reuters) - Regenxbio Inc  RGNX.O :
    * REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY
DUCHENNE®
TRIAL OF RGX-202
    * REGENXBIO INC - EXPECTS TO INITIATE PIVOTAL TRIAL IN Q4
2024
    * REGENXBIO INC - PATIENTS AGED 5.8 AND 8.5 YEARS HAD
EXPRESSION
LEVELS AT 77.2% AND 46.5% OF CONTROL
    * REGENXBIO: AS OF JULY 8, RGX-202 WELL TOLERATED WITH NO
SERIOUS
ADVERSE EVENTS
    * REGENXBIO INC - TO SHARE FUNCTIONAL ASSESSMENT DATA IN H2
2024

Source text for Eikon:  ID:nPn7w84tfa 
Further company coverage:  RGNX.O 

 (X)
 ((Reuters.Briefs@thomsonreuters.com;))